GlassScriptPhysician profile
Shoba Jayaram
NPI 1952795825
$3,923.79
in general payments reported to CMS, 2019-2025
25 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $168 · 2021: $415 · 2022: $606 · 2023: $1,072 · 2024: $827 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913 · Travel and Lodging: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.41 |
| Travel and Lodging | $508.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $830.98 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $666.05 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Livanova USA, INC. | $508.31 | 2023 | Vns Therapy |
| Pfizer INC. | $224.91 | 2025 | |
| Tg Therapeutics, INC. | $189.45 | 2023-2025 | |
| Averitas Pharma INC. | $153.90 | 2024 | Qutenza |
| Genentech, INC. | $140.64 | 2024 | Ocrevus |
| Genzyme Corporation | $137.89 | 2019 | |
| Mallinckrodt Enterprises LLC | $110.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $109.03 | 2021-2023 | |
| Csl Behring | $97.58 | 2021 | |
| Argenx US, INC. | $90.93 | 2025 | Vyvgart |
| Janssen Pharmaceuticals, INC | $90.10 | 2022 | |
| Sk Life Science, INC. | $90.06 | 2020-2023 | Xcopri |
| Mdd US Operations, LLC | $89.21 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $84.35 | 2024 | Ocrevus |
| Ucb, INC. | $72.84 | 2020 | |
| Biogen, INC. | $58.20 | 2021 | |
| Eisai INC. | $45.60 | 2020 | |
| Sunovion Pharmaceuticals INC. | $31.81 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.45 | 2022 | |
| Neurocrine Biosciences, INC. | $23.05 | 2023 | Ongentys, Ingrezza |
| Acorda Therapeutics, INC | $19.15 | 2019 | |
| Avanir Pharmaceuticals, INC. | $18.04 | 2019 | |
| Amgen INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shoba Jayaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.